Lead Product(s): N-Desethyloxybutynin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
New chemical entity and selective muscarinic receptor antagonist targeting large unmet need for a new treatment that can meaningfully improve the lives of patients with neurological conditions.